AR114418A1 - Compuesto cíclico de metilactama y su utilización farmacéutica - Google Patents
Compuesto cíclico de metilactama y su utilización farmacéuticaInfo
- Publication number
- AR114418A1 AR114418A1 ARP190100503A ARP190100503A AR114418A1 AR 114418 A1 AR114418 A1 AR 114418A1 AR P190100503 A ARP190100503 A AR P190100503A AR P190100503 A ARP190100503 A AR P190100503A AR 114418 A1 AR114418 A1 AR 114418A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical use
- methylactam
- cyclic compound
- pharmaceutical
- compound
- Prior art date
Links
- 150000001923 cyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 108091006277 SLC5A1 Proteins 0.000 abstract 1
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018036307 | 2018-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114418A1 true AR114418A1 (es) | 2020-09-02 |
Family
ID=67806229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100503A AR114418A1 (es) | 2018-03-01 | 2019-02-28 | Compuesto cíclico de metilactama y su utilización farmacéutica |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11014910B2 (https=) |
| EP (1) | EP3760624A4 (https=) |
| JP (3) | JP7206132B2 (https=) |
| KR (1) | KR102795351B1 (https=) |
| CN (1) | CN111757877B (https=) |
| AR (1) | AR114418A1 (https=) |
| AU (1) | AU2019227770B2 (https=) |
| BR (1) | BR112020016788A2 (https=) |
| CA (1) | CA3087859A1 (https=) |
| CL (1) | CL2020002199A1 (https=) |
| IL (1) | IL276311B2 (https=) |
| MA (1) | MA52427A (https=) |
| MX (1) | MX2020009070A (https=) |
| MY (1) | MY205197A (https=) |
| PE (1) | PE20210123A1 (https=) |
| PH (1) | PH12020551340A1 (https=) |
| SA (1) | SA520420037B1 (https=) |
| SG (1) | SG11202007120UA (https=) |
| TW (1) | TWI805699B (https=) |
| WO (1) | WO2019168096A1 (https=) |
| ZA (1) | ZA202004600B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI805699B (zh) * | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| EP3778593A4 (en) | 2018-04-04 | 2021-12-22 | Japan Tobacco Inc. | HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE |
| JP7760370B2 (ja) * | 2019-09-04 | 2025-10-27 | 日本たばこ産業株式会社 | 慢性腎臓病の治療又は予防方法 |
| US20230119894A1 (en) * | 2019-09-04 | 2023-04-20 | Japan Tobacco Inc. | Therapeutic or prophylactic method for diabetes using combination medicine |
| CA3175131A1 (en) | 2020-03-19 | 2021-09-23 | Chihiro Okuma | Treatment or prevention method for chronic heart failure |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657282A (en) * | 1969-01-23 | 1972-04-18 | Merck & Co Inc | Carboxyepoxyethyl-1-phosphonic acid and derivatives |
| FR2665898B1 (fr) | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| JPH04247081A (ja) | 1991-02-01 | 1992-09-03 | Takeda Chem Ind Ltd | ５員複素環酸アミド類 |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US7622471B2 (en) | 2003-02-07 | 2009-11-24 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives having a pyridazine and pyridine functionality |
| AU2004200420A1 (en) | 2003-03-11 | 2004-09-30 | Astellas Pharma Inc. | Inhibitor of cyclooxygenase |
| JP2006182648A (ja) | 2003-04-08 | 2006-07-13 | Dai Ichi Seiyaku Co Ltd | ７員複素環誘導体 |
| WO2004110351A2 (en) | 2003-05-14 | 2004-12-23 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis c virus |
| TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
| TW200526641A (en) | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
| CN1980665A (zh) | 2004-07-07 | 2007-06-13 | 默克公司 | 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法 |
| AU2005305675B2 (en) | 2004-11-16 | 2012-12-13 | Jazz Pharmaceuticals Operations Uk Limited | New use for cannabinoid |
| JP2008007405A (ja) | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | カルボキサミド誘導体 |
| JP4137956B2 (ja) * | 2005-06-08 | 2008-08-20 | 日本たばこ産業株式会社 | 複素環化合物 |
| KR100970294B1 (ko) | 2005-06-08 | 2010-07-15 | 니뽄 다바코 산교 가부시키가이샤 | 복소환 화합물 |
| ZA200800142B (en) * | 2005-06-08 | 2009-05-27 | Japan Tobacco Inc | Heterocyclic compound |
| WO2007034279A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
| WO2007098826A2 (en) | 2006-01-18 | 2007-09-07 | Siena Biotech S.P.A. | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| EP2026798A1 (en) * | 2006-04-27 | 2009-02-25 | Solvay Pharmaceuticals GmbH | Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators |
| US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
| KR101450356B1 (ko) | 2006-11-24 | 2014-10-15 | 에이씨 이뮨 에스.에이. | 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체 |
| EP2121619A2 (en) | 2006-11-24 | 2009-11-25 | AC Immune S.A. | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| JP5583003B2 (ja) * | 2007-04-02 | 2014-09-03 | セラコス・インコーポレイテッド | ベンジルグルコシド誘導体およびその用途 |
| WO2009091813A1 (en) | 2008-01-14 | 2009-07-23 | Wyeth | Compounds useful as alpha7 nicotinic acetylcholine receptor agonists |
| EP2349484A2 (en) | 2008-07-15 | 2011-08-03 | Novartis AG | Heteroaryl derivatives as dgat1 inhibitors |
| CN102918034B (zh) | 2010-03-30 | 2015-06-03 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| KR102727059B1 (ko) * | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| CN109071454B (zh) * | 2016-02-16 | 2023-02-17 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| TWI805699B (zh) * | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| EP3778593A4 (en) | 2018-04-04 | 2021-12-22 | Japan Tobacco Inc. | HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE |
-
2019
- 2019-02-27 TW TW108106807A patent/TWI805699B/zh active
- 2019-02-28 AR ARP190100503A patent/AR114418A1/es unknown
- 2019-02-28 MX MX2020009070A patent/MX2020009070A/es unknown
- 2019-02-28 CN CN201980016238.4A patent/CN111757877B/zh active Active
- 2019-02-28 WO PCT/JP2019/007799 patent/WO2019168096A1/ja not_active Ceased
- 2019-02-28 MY MYPI2020003891A patent/MY205197A/en unknown
- 2019-02-28 US US16/289,500 patent/US11014910B2/en active Active
- 2019-02-28 MA MA052427A patent/MA52427A/fr unknown
- 2019-02-28 PE PE2020001287A patent/PE20210123A1/es unknown
- 2019-02-28 AU AU2019227770A patent/AU2019227770B2/en active Active
- 2019-02-28 KR KR1020207025856A patent/KR102795351B1/ko active Active
- 2019-02-28 SG SG11202007120UA patent/SG11202007120UA/en unknown
- 2019-02-28 IL IL276311A patent/IL276311B2/en unknown
- 2019-02-28 BR BR112020016788-6A patent/BR112020016788A2/pt active Search and Examination
- 2019-02-28 JP JP2019035140A patent/JP7206132B2/ja active Active
- 2019-02-28 CA CA3087859A patent/CA3087859A1/en active Pending
- 2019-02-28 EP EP19760111.5A patent/EP3760624A4/en active Pending
-
2020
- 2020-07-24 ZA ZA2020/04600A patent/ZA202004600B/en unknown
- 2020-08-24 SA SA520420037A patent/SA520420037B1/ar unknown
- 2020-08-26 CL CL2020002199A patent/CL2020002199A1/es unknown
- 2020-08-27 PH PH12020551340A patent/PH12020551340A1/en unknown
-
2021
- 2021-04-16 US US17/233,273 patent/US20220064148A1/en not_active Abandoned
-
2023
- 2023-01-04 JP JP2023000037A patent/JP2023026566A/ja active Pending
- 2023-06-28 US US18/343,415 patent/US20240174646A1/en not_active Abandoned
-
2024
- 2024-12-09 JP JP2024214451A patent/JP2025026615A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114418A1 (es) | Compuesto cíclico de metilactama y su utilización farmacéutica | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| MX2023011675A (es) | Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia. | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| ECSP20035590A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
| AR053162A1 (es) | Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma. | |
| BR112015030399B8 (pt) | Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3 | |
| MX2018009459A (es) | Derivado de sulfonamida y composicion farmaceutica que contiene el mismo. | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| MX2021009971A (es) | Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. | |
| MX2021008432A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
| CL2021002480A1 (es) | Agonistas compuestos macrocíclicos como de sting | |
| BR112021023927A2 (pt) | Composto, e, composição farmacêutica | |
| WO2016068580A3 (en) | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) | |
| AR095032A1 (es) | Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo | |
| MX2022003504A (es) | Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo. | |
| MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
| MX2019012522A (es) | Compuestos y metodos terapeuticos. | |
| BR112017015744A2 (pt) | composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas | |
| CL2017002229A1 (es) | Inhibidores de bace1. |